Outcomes and safety of low dose nivolumab in patients with palliative head and neck cancer: A retrospective audit from Nepal

Introduction Palliative patients of head and neck cancer have very few treatment options with significant side effects. This study evaluated the safety and efficacy of low dose Nivolumab in palliative head and neck cancer cases. Methodology The study was a retrospective study of 71 palliative patients of head and neck cancer (palliative either after initial chemotherapy, radiotherapy or chemoradiotherapy and upfront palliative cases) from Feb 2022 to Feb 2025. Patients' data were extracted who were treated with low dose Nivolumab 20 mg 3 weekly with or without oral metronomic agents. Gefitinib 250 mg daily and Methotrexate 10 mg once weekly was given with Nivolumab 20 mg IV 3 weekly regimen. ORR after three and six cycles of Nivolumab were assessed. Adverse effects were recorded as per CTCAE version 5.0. Overall survival and progression free survival with respect to response rate were assessed and presented in percentages and graphs. Results Most common cases were of oral cavity cancer (43.66%) followed by larynx (30.99%), oropharynx (16.90%) and hypopharynx (8.45%). The ORR is 53.51% in our study with CR of 15.49%, and PR of 38.02%0.16 patients (22.53%) had SD while 17 (23.94%) patients had PD. One-year overall survival for patients with CR was 81.8%, PR was 33.3%. One-year PFS for patients with CR is 27.3% and PR is 3.7% while it is nil in patients having SD and PD). Most common side effects in our study were fatigue (59.15%) and gastritis (57.74%). Conclusion The early results with low dose Nivolumab are reasonable in terms of response rate and manageable side effects. The observed responses reflect the combined effect of low dose nivolumab with or without prior therapies, and that the independent contribution of nivolumab cannot be determined from this study design.

Authors

Institutions

Publication Details

Journal
Heliyon
Published
2026-11-16
DOI
https://doi.org/10.1016/j.heliyon.2026.e45741
Primary Topic
Head and Neck Cancer Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Outcomes and safety of low dose nivolumab in patients with palliative head and neck cancer: A retrospective audit from Nepal

Archana Amatya, Suraj Suwal, Deep Lamichhane, Shweta Baral et al.
1 links
Heliyon
Head and Neck Cancer Studies
article

Outcomes and safety of low dose nivolumab in patients with palliative head and neck cancer: A retrospective audit from Nepal

Archana Amatya, Suraj Suwal, Deep Lamichhane, Shweta Baral, Sudhir Raj Silwal, Bibek Khanal
article en

Abstract

Introduction Palliative patients of head and neck cancer have very few treatment options with significant side effects. This study evaluated the safety and efficacy of low dose Nivolumab in palliative head and neck cancer cases. Methodology The study was a retrospective study of 71 palliative patients of head and neck cancer (palliative either after initial chemotherapy, radiotherapy or chemoradiotherapy and upfront palliative cases) from Feb 2022 to Feb 2025. Patients' data were extracted who were treated with low dose Nivolumab 20 mg 3 weekly with or without oral metronomic agents. Gefitinib 250 mg daily and Methotrexate 10 mg once weekly was given with Nivolumab 20 mg IV 3 weekly regimen. ORR after three and six cycles of Nivolumab were assessed. Adverse effects were recorded as per CTCAE version 5.0. Overall survival and progression free survival with respect to response rate were assessed and presented in percentages and graphs. Results Most common cases were of oral cavity cancer (43.66%) followed by larynx (30.99%), oropharynx (16.90%) and hypopharynx (8.45%). The ORR is 53.51% in our study with CR of 15.49%, and PR of 38.02%0.16 patients (22.53%) had SD while 17 (23.94%) patients had PD. One-year overall survival for patients with CR was 81.8%, PR was 33.3%. One-year PFS for patients with CR is 27.3% and PR is 3.7% while it is nil in patients having SD and PD). Most common side effects in our study were fatigue (59.15%) and gastritis (57.74%). Conclusion The early results with low dose Nivolumab are reasonable in terms of response rate and manageable side effects. The observed responses reflect the combined effect of low dose nivolumab with or without prior therapies, and that the independent contribution of nivolumab cannot be determined from this study design.

HeliyonVol. 12(17)
Bhaktapur Cancer Hospital (NP)
Good health and well-being
Head and Neck Cancer Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon